-
Artificial intelligence expedites breast cancer risk prediction
Sep 1, 2016, 13:08 PM by Michael CroftHOUSTON, TX, UNITED STATES - Sep 1, 2016 - Researchers at Houston Methodist have developed an artificial intelligence (AI) software that reliably interprets mammograms, assisting doctors with a quick and accurate prediction of breast cancer riskFull story -
Cenduit Enhances IRT System with New Drug Management Modules
Sep 1, 2016, 09:55 AM by Michael CroftRESEARCH TRIANGLE PARK, NC, UNITED STATES - Sep 1, 2016 - Cenduit Enhances IRT System with New Drug Management ModulesAdvancements designed to improve efficiency and strengthen patient safetyCenduit, a joint venture between Quintiles and Thermo Fisher Scientific, today announced the launch of new drug management modules for its industry-leading interactive response technology (IRT) systemFull story -
FEI Celebrates Shipment of 1,000th Helios DualBeam System
Aug 31, 2016, 18:43 PM by Michael CroftHILLSBORO, OR - Aug 31, 2016 - FEI (NASDAQ: FEIC) today announced a milestone of the 1,000th Helios DualBeam system shipped since the product family was introduced in 2006Full story -
Biogen’s Plaque-Busting Alzheimer’s Drug Shows Promise
Aug 31, 2016, 14:48 PM by Michael CroftMIT Technology Review | An antibody that clears up brain-destroying plaques may settle the cause of Alzheimer's once and for all.Full story -
How DNA Could Store All the World’s Data
Aug 31, 2016, 11:33 AM by Michael CroftNature News & Comment | Modern archiving technology cannot keep up with the growing tsunami of bits. But nature may hold an answer to that problem already.Full story -
Novartis Dissolves CAR-T Unit Cutting 120 Positions
Aug 31, 2016, 11:32 AM by Michael CroftForbes | Novartis is shutting down the business unit it created to develop white blood cells that can attack certain types of cancer, but continuing to develop such projects known as chimeric antigen receptor T-cells, or CAR-Ts.Full story -
Recipharm establishes long term supply agreement with Tillotts Pharma AG
Aug 31, 2016, 05:28 AM by Michael CroftSTOCKHOLM, SWEDEN - Aug 31, 2016 - Recipharm, the contract development and manufacturing organisation (CDMO), announces that it has entered into a long term supply agreement with Tillotts Pharma AGFull story -
Say hello to Dell Technologies on Sept. 7
Aug 30, 2016, 16:46 PM by Michael CroftComputerworld | Dell will complete its acquisition of EMC on Sept. 7, ending nearly a year of approvals and decades of history for the two companies that will combine to become Dell Technologies.Full story -
Excel Auto-Correct Creates Problems With Genomics Research
Aug 30, 2016, 13:14 PM by Michael CroftPCMAG | An Excel auto-correct feature changes gene names to dates. An Australian group dug through 7,500 Excel files published in 18 journals. About 20% of the files had errors.Full story -
tranSMART, IDBS, JAX and more: News from August 2016
Aug 30, 2016, 10:45 AM by Michael CroftBio-IT World News Briefs | News, products, and partnerships from around the bio-IT community including news from tranSMART, JAX, Internet2, IDBS, Synthego, and more.Full story -
The Genetics of Type 2 Diabetes Is a Mess
Aug 29, 2016, 13:06 PM by Michael CroftPacific Standard | A recent study shows why genetic advances in medicine are so challenging.Full story -
Recipharm increases lyophilisation capacity in Italy
Aug 26, 2016, 12:15 PM by Michael CroftMASATE, ITALY - Aug 26, 2016 - Recipharm, the contract development and manufacturing organisation (CDMO), has announced a €3.7 million investment to expand its lyophilisation capacity in Masate, Italy, in response to growing customer demandFull story -
Digitizing The Pharma Research Value Chain For Faster Drug Discovery Through Precompetitive Collaboration
Aug 26, 2016, 09:45 AM by Michael CroftFull storyBio-IT World Contributed Commentary | The global pharmaceutical industry is at a crossroads. It is, therefore, imperative for pharma organizations to reimagine their research value chain, in order to accelerate product innovation, and boost molecule pipelines during the discovery stage.
-
Stealthy Biotech Revives Stalled Parkinsons Drug Reveals Plans In Alzheimers and ALS
Aug 25, 2016, 17:19 PM by Michael CroftForbes | Denali Therapeutics, the stealthy South San Francisco biotech startup that raised $217 million last year to fight Alzheimer's, Parkinson's and ALS, is finally lifting the curtain on its plans this morning.Full story -
Bio-Rad Introduces an Assay Website That Allows Researchers to Identify or Design Their Own Droplet Digital™ PCR Assays
Aug 24, 2016, 18:23 PM by Michael CroftHERCULES, CA, UNITED STATES - Aug 9, 2016 - Bio-Rad Laboratories Inc. (NYSE: BIO and BIOb) today announced the launch of an assay website that allows droplet digital PCR (ddPCR) users to locate existing assays or design new ones for mutation detection and copy number determinationFull story -
Bioclinica Enters Agreement to be Acquired by Cinven
Aug 23, 2016, 11:41 AM by Michael CroftDOYLESTOWN, PA, US - Aug 23, 2016 - Bioclinica®, a provider of specialized technology-enabled services supporting clinical trials, today announced that it has entered a definitive agreement to be acquired by Cinven, a leading international private equity firmFull story -
MDI Biological Laboratory Scientists Awarded Patent for Potential New Heart Disease Drug
Aug 23, 2016, 11:34 AM by Michael CroftBAR HARBOR, ME - Aug 23, 2016 - The U.S. Patent and Trademark Office has announced that it will grant a patent to MDI Biological Laboratory scientists Voot PFull story -
Is the virtual gene panel the way forward, asks Congenica at Dx Summit
Aug 23, 2016, 07:54 AM by Michael CroftCAMBRIDGE, UNITED KINGDOM - Aug 23, 2016 - Although the current practice of analysing defined gene panels for a specific disease has great utility, it is of limited benefit when a condition is not well definedFull story -
Obama’s science legacy betting big on biomedical science
Aug 22, 2016, 13:30 PM by Michael CroftNature News & Comment | Ambitious bids to map the brain and cure cancer have not boosted overall research funding.Full story -
With $14 Billion Purchase Pfizer Signals That Cancer Drug Prices Will Remain High
Aug 22, 2016, 13:20 PM by Michael CroftForbes | Pfizer says it will purchase biotechnology upstart Medivation for $14 billion in cash. The main prize in the deal: Medivation's prostate cancer drug, Xtandi, which costs $120,000 a year.Full story